Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bayer HealthCare Pharmaceuticals; Onyx Pharmaceuticals, Inc.
The New England Journal of Medicine Publishes Nexavar Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
August 5th, 2008
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that The New England Journal of Medicine published results of a Phase 3 trial demonstrating that Nexavar(R) (sorafenib) tablets decreased the absolute risk of death by 31 percent in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, versus patients who received placebo. This represents a 44 percent improvement in median overall survival for patients treated with Nexavar. Based on the strength of these data, Nexavar was approved for HCC by the European Agency for the Evaluation of Medicinal Products (EMEA) and by the U.S. Food and Drug Administration (FDA) in...
Source: Cancer Weekly (2008-08-05)
|
